1. Home
  2. FUSE vs BOLD Comparison

FUSE vs BOLD Comparison

Compare FUSE & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FUSE

Fusemachines Inc.

N/A

Current Price

$1.41

Market Cap

40.8M

Sector

Technology

ML Signal

N/A

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$1.44

Market Cap

36.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
FUSE
BOLD
Founded
2013
2018
Country
United States
United States
Employees
270
N/A
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
40.8M
36.5M
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
FUSE
BOLD
Price
$1.41
$1.44
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.00
AVG Volume (30 Days)
149.6K
130.8K
Earning Date
06-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
32.47
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.80
$0.96
52 Week High
$3.67
$1.68

Technical Indicators

Market Signals
Indicator
FUSE
BOLD
Relative Strength Index (RSI) 45.53 48.89
Support Level $1.28 $1.42
Resistance Level $1.50 $1.55
Average True Range (ATR) 0.15 0.09
MACD -0.03 -0.02
Stochastic Oscillator 26.32 20.75

Price Performance

Historical Comparison
FUSE
BOLD

About FUSE Fusemachines Inc.

Fusemachines Inc is a provider of enterprise AI solutions, offering products such as AI Studio, AI Engines, and AI Agents, along with supporting services across various industries. Its solutions are supported by a talent pool from underserved communities, enabling scalable and high-quality AI delivery while promoting access to AI. The Company serves clients across industries, including healthcare, media, technology, and government, helping address challenges such as improving forecasting accuracy, reducing data entry errors, automating recruitment, and detecting fraud. Its product suite includes AI Studio, AI Engines, and AI Agents, designed to build, deploy, and scale AI solutions, and it operates in Nepal and the United States.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: